Introduction 1
In heart failure (HF) populations, prognosis is poor and optimization of HF treatment and 2 common comorbidities are fundamental to improving prognostic outcomes such as hospitalization and 3 death. Type-2 diabetes (T2D) is one of the most common comorbidities in HF impacting approximately 4 a third of all patients(1). Despite early promise from new 'add-on' pharmacotherapies for T2D such as 5 sodium-glucose cotransporter 2 (SGLT2) inhibitors(2), T2D is associated with a significantly high risk of 6 adverse outcomes in HF(3). Management of T2D is centred around three key metabolic markers; 7 haemoglobin A1C (HbA1c), blood pressure and low density lipoprotein(4) and guidelines advocate 8 target-based individualised treatment (i.e. reducing HbA1c to below a specific concentration)(5) often 9 necessitating the addition of further glucose-lowering therapies over time and the attendant risk of 10 hypoglycemia (6). Treatment of HF patients with T2D can therefore be compounded by polypharmacy 11 and uncertainty about the safety of some glucose lowering drug therapies particularly where renal 12 dysfunction also exists (7) . 13 Current evidence on T2D in HF is predominantly from trials or hospital based registries(8-10) 14 and there is extremely limited evidence on T2D in the general unselected HF population. Furthermore 15 evidence has included the 'presence or absence' of T2D as a single baseline measure which treats HF 16 patients with diabetes as a homogenous group and ignores the potential importance of levels of 17 glycemic control and anti-diabetic treatment that vary over time. These measures are captured in 18 routine management of HF patients with T2D and may provide important indication of differential 19 prognostic risk in the larger general population where most of the chronic disease management is 20 carried out. 21 We used two case control studies nested within an incident cohort of general population HF 22 patients from the UK Clinical Practice Research Datalink (CPRD), to investigate the association 23 between T2D and subsequent risk of all-cause first hospitalization and mortality, compared to HF 24 5 patients without T2D. T2D patients were stratified by measures of glycemic control and anti-diabetic 25 drugs and by change in these measures recent to the chosen outcomes.
26

Methods
27
Study population 28 We conducted two case-control studies nested within the prospective CPRD database cohort 29 which covers approximately 10% of the UK general population(11). Anonymised data included 30 population demographic and lifestyle factors, clinical data on diagnoses, prescribed drugs and 31 laboratory tests, and linked to hospital admissions data based on Hospital Episode Statistics (HES) and 32 mortality data. Data was available for the time-period between 1 st January 2002 and 1 st January 2014 33 and CPRD permission for data access was under licence (protocol 12_162) with approval granted from 34 the Independent Scientific Advisory Committee. 35 We chose a nested case-control design to establish a specific temporal link between T2D 36 measures and their short term association with outcomes and to account for the varying nature of 37 glycemic control and drug treatments over time. Patients aged over 40 years were selected by a first 38 diagnostic HF code applied to clinical records in the 10 year time-period from 1 st January 2002 to 1 st 39 January 2012. Time for follow-up for each patient was from the date of the first HF code to either the 40 date of the patient transferring out of practice, the outcome event or the study end (1 st January 2014).
41
Presence of T2D in the HF population, after exclusion of T1D was based on clinical or drug codes 42 applied prior to the outcome event date and all patients had minimum 3-years of up to standard CPRD 43 data before study entry. The HF and T2D code sets were validated by clinicians and other CPRD 44 strategies(12,13)(Supplementary file).
46
Selection of cases and matched controls 47
For the CPRD sample with linked hospitalization data (n=27,283), the outcome event date was 48 defined by the first all-cause hospitalization after, but not including the HF diagnosis date. All-cause 49 mortality data was available for the whole cohort (n=48,978) and the outcome event date was defined 50 as the date of all-cause death. For both analyses, all cases were matched on the outcome event date 51 with up to four controls randomly sampled from the HF cohort still at risk of the event. Matching was by 52 the HF diagnosis date (+/-1 month) and duration of follow-up. Using this approach controls are eligible 53 to be selected multiple times and later as a case, approximating the situation in Cox-regression and 54 unbiased estimates of rate ratio, comparable to other cohort analyses can be calculated (14) . 
58
Glycemic control was measured by the most recent HbA1c level recorded on or before the outcome 59 date, but values were excluded if they were recorded more than 6-months before the outcome date for 60 first hospitalization and 12-months for mortality. T2D patients were stratified into six HbA1c categories; 61 <5.5%, 5.5-6.4%, 6.5-7.5%, 7.6-8.5%, 8.6-9.5% and >9.5%. Change in glycemic control was measured 62 using two HbA1c values (the most recent value as outlined above and a previous value separated by at 63 least 3 months). For hospitalization analyses, previous values were excluded if they were more than 12 64 months before the recent value. For mortality analyses values were excluded if they were more than 65 three years before the recent value. The difference between the two values was then adjusted for the 66 interval time to calculate change in HbA1c over the 6-months for hospitalization and 12-months for all-67 cause mortality. Patients with T2D were categorised into the following change groups; an absolute 68 increase in HbA1c of >1%, decrease of >1% or minimal change ≤1%.
69
T2D patients were separately stratified by four a priori ordinal categories of drug treatment 70 intensity and three categories of drug treatment change. Drug treatment intensity levels were (i) none,
71
(ii) oral anti-hyperglycemic only, (iii) oral anti-hyperglycemic plus insulin and (iv) insulin only. GLP-1 72 receptor agonists were only prescribed in very low numbers (248 patients in total) so for simplicity were 73 included in the oral group. Treatment status was based on drug prescribing recorded in the 4-months 74 7 period before the outcome date. The change categories were measured in two four month time-75 windows separated by an interval of 6 months for hospitalization or 12 months for all-cause mortality.
76
Change was based on an increase in at least one of the defined drug treatment categories, or a 77 decrease in at least one of the defined drug categories or no change of treatment in the defined change 78 windows.
79
Measurement of confounding 80
Confounders were selected using current evidence(1) which included age, sex, body mass 81 index (BMI), smoking, alcohol, cholesterol, Hemoglobin, blood pressure (BP), estimated glomerular 82 filtration rate (eGFR), hypertension, ischaemic heart disease (IHD), previous myocardial infarction, 83 atrial fibrillation and chronic obstructive pulmonary disease. The Index of Multiple Deprivation was also 84 included which is a score relating to the individual patient postcode that combines seven weighted 85 indicators covering economic, health, social and housing domains into a single deprivation score(15).
86
For these confounders the most recent measure before the outcome date was used. Drug measures for 87 aspirin, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers and 88 diuretics were also extracted in a 4-month time window before the outcome date. For each outcome analysis, the case and control status is first presented to compare patient 92 and clinical characteristics. To build the multivariable models, linearity was investigated using likelihood 93 ratio tests and quadratic terms were added for continuous variables where necessary. For correlated 94 variables with coefficient >0.5, the most clinically relevant one was selected. First order interactions 95 terms were included in a full multivariable model to examine the relationship between diabetes and age, 96 sex and renal function for both outcomes. Then, for the two outcomes, multiple imputation was 97 performed for the missing confounder data (<20%) using matching variables and full-conditional 98 specification in StataMP 13 and analyses were combined using Rubin's rules (16).
99
Presence of T2D in HF patients was significantly associated with first hospitalization (aOR 125 1.29, 1.24-1.34) ( Table 2 ) and this risk was higher in older than younger groups and in females than 126 males ( Supplementary Table 1 ). Presence of T2D in HF patients was also significantly associated with 127 all-cause mortality (aOR 1.24,1.29-1.40) ( Table 3) which was higher in the younger (1.35,1.25-1.45) 128 than the older group (1.20,1.14-1.28) ( Supplementary Table 2 ). (Figure 1) . The highest risk was 134 in the HbA1c >9.5% group with an aOR of 1.75 (1.52-2.02) which was significantly higher than the 135 lowest risk HbA1c groups which were 5.5-6.4% (1.13,1.03-1.24) and 6.5-7.5% (1.13,1.05-1.22) ( Table   136 2). 137 In categories of drug treatment intensity, there was incremental significant association of 138 increased risk of first hospitalization, from the T2D group without medications ( A recent HbA1c measure within 12 months of mortality was recorded in 83% of the matched 144 sample. In strata of HbA1c, T2D patients also showed a U-shaped relationship with mortality compared 145 to the HF group without T2D (Table 3 and Figure 2) . The estimate for HbA1c group <5.5% was aOR 146 1.29 (1.10-1.51) and the HbA1c group >9.5% was 1.30 (1.24-1.47) for mortality. This was significantly 147 higher than the lowest risk HbA1c 6.5-7.5% group, 1.10 (1.03-1.17).
148
In terms of drug treatment intensity, the strongest associations with mortality were for T2D 149 patients without drug treatment (aOR 1.31,1.23-1.39) and insulin only (1.43,1.31-1.57) which were 150 significantly higher than the oral anti-hyperglycemic group (1.16,1.11-1.22 Finally, all sensitivity analyses are presented in supplementary tables 3 to 5. Adjustment of the 178 mortality models with Index Multiple Deprivation had minimal non-significant influence on effect 179 estimates. When the oral T2D group was categorised by different drug types, those prescribed 180 metformin were associated with less risk of both outcomes than those prescribed other anti-diabetic 181 drugs which was significant for all-cause mortality. The risk association between increased HbA1c level 182 and hospitalization was greater in patients with a high start and end HbA1c value. The high risk 183 association between decreasing HbA1c level and all-cause mortality was not influenced by the start or 184 end HbA1c value. In terms of T2D duration, risk of both outcomes was significantly higher for those with 185 T2D onset before HF than for T2D onset after HF. The highest risk of hospitalization and all-cause death was associated with the T2D group on 197 insulin, consistent with previous hospital HF studies (20, 21) . This group tends to indicate patients with 198 poor control in T2D with more severe metabolic disturbances and increased severity(22). However, an 199 elevated risk of all-cause mortality was also associated with the T2D without drug treatment. Diabetes 200 studies have shown diet-controlled diabetics have better glycemic control and less complications(23) 201 and in HF that T2D treated with metformin can be protective compared to no drug treatments (24). The 202 high risk in the no-medications group in this study in the 4-months prior to death likely reflects end-203 stage HF severity where de-prescribing may occur(25). linear association was found between increasing HbA1c and increasing mortality risk but in other non-209 trial HF populations a similar U-shaped association has been reported (6, 26, 27) . The prior non-trial 210 studies were based on small select samples but patients were generally older with a higher proportion 211 of people with more advanced HF disease than in the CHARM trial. By studying a large sample of the 212 general HF population our data adds to and supports a more complex relationship between HbA1c and 213 outcomes in HF. Whilst our study sample was from the general HF population, measurement of HbA1c 214 was in the imminent time-period prior to admission or death and the associated risk likely reflects the 215 more severe HF group which is congruent with the prior evidence in more advanced disease (26). This 216 'reverse epidemiology' where known risk factors improve survival in HF has been related previously to 217 more advanced disease(31). Whilst the study findings point to the importance of low as well as high 218 HbA1c for outcome risk we did not include individual or repeated hypoglycemic events in our analyses 219 which have previously been shown to be associated with increased risk of cardiovascular events and 220 death in T2D patients (32) . Future investigation of the relationship between low HbA1c, rate of 221 hypoglycemic events and outcomes would further delineate these associations. 222 We found the lowest risk HbA1c level for all-cause mortality reflected current international 223 diabetic guidelines(5), but the level was even lower for first hospitalization. A shift to the right in the U 224 curve has been found previously in more advanced disease suggesting a lower threshold for 225 hypoglycemia(28). The different HbA1c levels of risk for the two outcomes in part reflects that HF 226 severity may be higher for patients close to death compared to those at risk of the first 227 hospitalization(29). This implies that the target for HbA1c control needs to be guided by the severity of 228 the HF with higher level targets in more severe disease and with more scope for intensive glucose 229 lowering therapy in less severe HF. In the general HF population, around a quarter of T2D patients The study was retrospective and observational in nature so measurements were based on 246 routine practice and HF diagnosis from the general population. Routine data can be subject to 247 misclassification leading to over-ascertainment of HF or under-ascertainment of DM. However, 248 accuracy of diagnosis within the CPRD has been found to be valid for a range of morbidities(11) 249 including HF and T2D(12, 14) . The definitions provide the real world context for the general HF 250 population and any misclassification would likely bias the results towards the null value. The clinical 251 diagnosis of T2D was based on drug and clinical codes to improve identification but cardiac imaging 252 data was not available so we were unable to further phenotype HF or provide specific risk estimates for 253 preserved or reduced ejection fraction status. Similarly, indicators of HF severity were not available so 254 we were not able to investigate the influence of HF severity on the associations between T2D Our study showed that measures of T2D status and treatments were associated with differential risk of The T2D group was stratified by categories of HbA1c and compared to HF patients without T2D for occurrence of a first 'any-285 cause' hospitalization after the HF incidence date.
287
Figure 2: HbA1c adjusted associations with all-cause mortality 288
The T2D group was stratified by categories of HbA1c and compared to HF patients without T2D for 'any-cause' death after 289 the HF incidence date.
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